Intellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($0.92), $0.09 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $13.78 million versus the consensus estimate of $14.06 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.